文献速递淋巴瘤白血病

BCL2家族基因失调及表观遗传修饰导致血液系统恶性肿瘤对维奈克拉耐药

Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies.
PubMed 文献 · Blood · 2022-01-01

该研究采用全外显子测序、甲基化DNA免疫沉淀测序和全基因组CRISPR/Cas9筛选,探究侵袭性淋巴瘤和高危慢性淋巴细胞白血病(CLL)患者对维奈克拉的耐药机制。研究发现PUMA启动子内CpG岛在维奈克拉治疗后发生甲基化,介导PUMA转录和蛋白水平下调;抑制甲基转移酶可恢复PUMA表达及对维奈克拉的敏感性。BAX缺失见于维奈克拉治疗失败后的Richter综合征患者,BAX介导的凋亡对耐药至关重要;TRAIL介导的凋亡及抗体或CAR T细胞可克服维奈克拉耐药。

要点

  • 维奈克拉治疗后PUMA启动子CpG岛甲基化导致PUMA下调,抑制甲基转移酶可恢复PUMA表达及药物敏感性。
  • PUMA缺失引起代谢重编程,氧化磷酸化和ATP产生增高,模拟维奈克拉耐药时的代谢表型。
  • BAX缺失见于维奈克拉治疗失败后的Richter综合征患者,BAX介导凋亡对耐药关键;TRAIL及抗体或CAR T细胞可清除耐药细胞。

核心结论

  • BCL2家族基因的表观遗传修饰(PUMA启动子甲基化)和基因失调(BAX缺失)导致血液系统恶性肿瘤对维奈克拉耐药。
  • 抑制甲基转移酶可恢复PUMA表达和对维奈克拉的敏感性;TRAIL介导的凋亡及抗体或CAR T细胞可克服维奈克拉耐药。

研究设计与样本

  • 研究采用全外显子测序、甲基化DNA免疫沉淀测序和全基因组CRISPR/Cas9筛选,纳入侵袭性淋巴瘤和高危CLL患者样本。
  • 研究比较了获得性维奈克拉耐药与获得性MCL1耐药、化疗耐药后CLL患者的样本,并分析了维奈克拉治疗失败后的Richter综合征患者。

主要发现

  • 维奈克拉治疗后PUMA启动子内调控性CpG岛发生甲基化,导致PUMA转录和蛋白水平下调。
  • 抑制甲基转移酶可恢复PUMA表达及对维奈克拉的敏感性。
  • PUMA缺失导致代谢重编程,氧化磷酸化和ATP产生增高,类似维奈克拉耐药时的代谢表型。
  • PUMA缺失为获得性维奈克拉耐药所特有,不见于获得性MCL1耐药,也未见於化疗耐药后的CLL患者;BAX对维奈克拉和MCL1抑制的敏感性均必需。
  • 维奈克拉治疗失败后的Richter综合征患者中可见BAX缺失;体内实验表明BAX介导的凋亡对耐药关键,但对CLL向侵袭性弥漫大B细胞淋巴瘤的疾病进展不重要。

临床怎么用

  • 作者发现抑制甲基转移酶可恢复PUMA表达和对维奈克拉的敏感性。
  • 作者发现TRAIL介导的凋亡及抗体或CAR T细胞可清除维奈克拉耐药的淋巴瘤细胞,提出了一条临床可用的克服维奈克拉耐药的途径。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The BCL2 inhibitor venetoclax has been approved to treat different hematological malignancies. Because there is no common genetic alteration causing resistance to venetoclax in chronic lymphocytic leukemia (CLL) and B-cell lymphoma, we asked if epigenetic events might be involved in venetoclax resistance. Therefore, we employed whole-exome sequencing, methylated DNA immunoprecipitation sequencing, and genome-wide clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 screening to investigate venetoclax resistance in aggressive lymphoma and high-risk CLL patients. We identified a regulatory CpG island within the PUMA promoter that is methylated upon venetoclax treatment, mediating PUMA downregulation on transcript and protein level. PUMA expression and sensitivity toward venetoclax can be restored by inhibition of methyltransferases. We can demonstrate that loss of PUMA results in metabolic reprogramming with higher oxidative phosphorylation and adenosine triphosphate production, resembling the metabolic phenotype that is seen upon venetoclax resistance. Although PUMA loss is specific for acquired venetoclax resistance but not for acquired MCL1 resistance and is not seen in CLL patients after chemotherapy-resistance, BAX is essential for sensitivity toward both venetoclax and MCL1 inhibition. As we found loss of BAX in Richter's syndrome patients after venetoclax failure, we defined BAX-mediated apoptosis to be critical for drug resistance but not for disease progression of CLL into aggressive diffuse large B-cell lymphoma in vivo. A compound screen revealed TRAIL-mediated apoptosis as a target to overcome BAX deficiency. Furthermore, antibody or CAR T cells eliminated venetoclax resistant lymphoma cells, paving a clinically applicable way to overcome venetoclax resistance.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Thomalla D, Beckmann L, Grimm C, et al. Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies. Blood. 2022. PMID: 35704690. doi:10.1182/blood.2021014304

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。